Hologic (HOLX) Lowered to Sell at BidaskClub

BidaskClub cut shares of Hologic (NASDAQ:HOLX) from a hold rating to a sell rating in a research note published on Friday.

Other equities analysts have also issued reports about the stock. Leerink Swann lowered shares of Hologic from an outperform rating to a market perform rating and lowered their target price for the company from $48.00 to $41.00 in a report on Thursday, May 3rd. BTIG Research reiterated a buy rating and set a $44.00 target price on shares of Hologic in a report on Sunday, May 6th. Needham & Company LLC reiterated a buy rating and set a $50.00 target price on shares of Hologic in a report on Friday, February 9th. Zacks Investment Research lowered shares of Hologic from a hold rating to a sell rating in a report on Monday, April 30th. Finally, Canaccord Genuity lowered shares of Hologic from a buy rating to a hold rating and lowered their target price for the company from $48.00 to $39.00 in a report on Thursday, May 3rd. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $44.87.

HOLX traded up $0.20 on Friday, hitting $38.92. The company had a trading volume of 1,099,563 shares, compared to its average volume of 2,540,172. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.26 and a quick ratio of 0.98. Hologic has a 52-week low of $35.10 and a 52-week high of $46.80. The firm has a market capitalization of $10.57 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 1.82 and a beta of 0.87.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm had revenue of $789.30 million during the quarter, compared to analyst estimates of $781.23 million. During the same period last year, the business earned $0.50 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. analysts expect that Hologic will post 2.23 EPS for the current fiscal year.

In related news, VP Karleen Marie Oberton sold 12,196 shares of the business’s stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the completion of the transaction, the vice president now directly owns 13,825 shares in the company, valued at approximately $553,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles J. Dockendorff acquired 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was purchased at an average price of $38.80 per share, with a total value of $504,400.00. The disclosure for this purchase can be found here. 0.79% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Amalgamated Bank grew its position in Hologic by 4.6% in the 1st quarter. Amalgamated Bank now owns 37,694 shares of the medical equipment provider’s stock worth $1,408,000 after purchasing an additional 1,674 shares during the period. Principal Financial Group Inc. grew its position in Hologic by 0.5% in the 1st quarter. Principal Financial Group Inc. now owns 406,319 shares of the medical equipment provider’s stock worth $15,180,000 after purchasing an additional 2,131 shares during the period. CIBC World Markets Inc. bought a new stake in Hologic in the 1st quarter worth approximately $359,000. Legal & General Group Plc grew its position in Hologic by 2.4% in the 1st quarter. Legal & General Group Plc now owns 1,421,810 shares of the medical equipment provider’s stock worth $53,122,000 after purchasing an additional 33,131 shares during the period. Finally, Wexford Capital LP bought a new stake in Hologic in the 1st quarter worth approximately $344,000. Institutional investors own 99.80% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply